- Avenge Bio recently announced it raised $45 million in Series A funding. These are the details.
Avenge Bio — a biotechnology company developing the LOCOcyte immunotherapy platform for the precision administration of potent immune effector molecules to treat solid tumors — recently announced the closing of its Series A financing of $45 million. This funding round in financing was co-led by Perceptive Xontogeny Venture Fund and CAM Capital with participation from seed investor Longitude Capital and new investors Rock Springs Capital and Pappas Capital.
The proceeds from the Series A financing will be used for advancing Avenge Bio’s lead program AVB-001 through the filing of an Investigational New Drug (IND) application and into the clinic for the treatment of metastatic peritoneal cancers with a primary focus on recurrent and refractory ovarian cancer. And the company will also use the proceeds to continue the rapid development of its pipeline programs.
Avenge Bio board of directors will consist of Michael Heffernan, Josh Richardson, M.D., Paul Wotton, Ph.D., and new additions Scott Morenstein and Ben Askew, Ph.D.
“We are pleased to announce the closing the Series A financing, which will expedite the advancement of our lead program to the clinic. Avenge Bio was founded with a mission to focus on the large unmet need of treating cancers like ovarian cancer, which has limited treatment options and often comes with a poor prognosis. This funding will also allow us to continue expanding our pipeline, which, in addition to treating peritoneal cancers, includes treatments for lung and breast cancers.”
— Michael Heffernan, Chief Executive Officer and co-founder of Avenge Bio
“The LOCOcyte immunotherapy platform leverages synthetically engineered allogeneic (off-the-shelf) cells to locally modulate the immune cells by delivering high concentrations of native immune effector molecules, for a sustained and controlled period of time. This creates a robust local immune response in proximity to the tumor and a corresponding systemic immune response while avoiding the toxicities associated with the known systemic exposure of immunotherapies.”
— Omid Veiseh, Ph.D., co-founder of Avenge Bio
“Recurrent ovarian cancer is currently incurable. Patients are treated with multiple rounds of chemotherapy with invariable development of chemotherapy-resistant disease, resulting in a significant unmet need for novel therapeutic options, including effective immunotherapies. The LOCOcyte™ platform’s ability to engineer cells that can deliver immune effector molecules in the peritoneal tumor environment, the major site of ovarian cancer metastasis, holds the potential to meet this unmet need. I look forward to working with Avenge Bio as the company moves into the clinic.”
— Amir Jazaeri, M.D., Vice Chair for Clinical Research and the Director of the Gynecologic Cancer Immunotherapy Program in the Department of Gynecologic Oncology and Reproductive Medicine at the University of Texas MD Anderson Cancer Center
“Avenge Bio’s LOCOcyte platform has tremendous potential to change the way we address the treatment of solid tumors and the delivery of immunotherapy in addition to improving the quality of life for patients diagnosed with difficult to treat cancers. We believe the scientific approach, the rapid pace of development, and the leadership team’s proven expertise makes this a very compelling opportunity.”
— Josh Richardson, M.D., Managing Director of Longitude Capital